CASI Pharmaceuticals Inc. has received a delisting determination from the Nasdaq Stock Market after its market value of listed securities remained below the required minimum for 30 consecutive trading days, failing to regain compliance by the November 3, 2025 deadline. The company has appealed the determination and requested a hearing to present a plan for regaining compliance, which will temporarily prevent the suspension of its securities as the appeal process moves forward. CASI remains in discussions with Nasdaq and will update shareholders with further developments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109186), on November 10, 2025, and is solely responsible for the information contained therein.